Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy
Part of paid clinical trials in Shawnee Mission, Kansas.
- Sponsor
- Retina Associates, Kansas City
- Study ID
- NCT00516464
- Phase
- PHASE3
- Status
- Unknown
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Lucentis (ranibizumab) — DRUG
Study Details
Evaluation of ranibizumab on the ease and procedure and complication in proliferative diabetic retinopathy (PDR) requiring vitrectomy.
Key Dates
- First listed
- Aug 15, 2007
- Start date
- Aug 31, 2007
- Status verified
- Aug 2007
- Completion
- Aug 31, 2008
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
To evaluate the effect of ranibizumab on vitrectomy complications such as recurrent vitreous hemorrhage, postoperative retinal detachment rates, and development of intraoperative retinal breaks. [ Time Frame: 6 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Retina Associates, PA | Shawnee Mission | Kansas | 66204 | Gregory M Fox, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Shawnee Mission, KS
By condition
By specialty
By research site